National

Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, November 12, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Population, Safety, University, CD19, GM, Authorization, Degenerative disease, University of Birmingham, Conditional, MAA, European Commission, Graft-versus-host disease, Infection, MHRA, Disease, CEO, National, EMA, COVID, COVID-19, CMML, Non-Hodgkin lymphoma, Rapporteur, Hospital, Risk management, Holocene, CMA, CRP, Access, Time, Chronic myelomonocytic leukemia, Royal commission, Vaccination, Patent, NHL, Nasdaq, Patient, NIH, FDA, Pharmaceutical industry, Animal

Humanigen submitted the last of the planned modules on September 30, 2021.

Key Points: 
  • Humanigen submitted the last of the planned modules on September 30, 2021.
  • Third Quarter and Recent Highlights:
    European Commission selected Humanigens lenzilumab as one of the 10 most promising treatments for COVID-19.
  • Subsequent to September 30, 2021, the company received net proceeds of approximately $24.5 million under its At-the-Market offering program.
  • A summary of key financial highlights as of and for the three and nine months ended September 30, 2021 and 2020 is as follows ($ in thousands):
    Three Months Ended September 30,
    Nine Months Ended September 30,

Systems Planning and Analysis, Inc., Awarded HIRE Vets Gold Medal

Retrieved on: 
Friday, November 12, 2021
A-235 anti-ballistic missile system, Employment, Hypersonic speed, Defense industrial base, IBM Basic Programming Support, SSL (company), Policy, SPA, CEO, Radar, Safety, Veteran, OIP Sensor Systems, U.S. Department of Labor, Office of Inspector General, Multimedia, National, Workforce, U.S. Department of Defense Strategy for Operating in Cyberspace, National security, Compliance, Security, Gold, System, Labour, Risk management

ALEXANDRIA, Va., Nov. 12, 2021 /PRNewswire/ -- The U.S. Department of Labor has awarded Systems Planning and Analysis, Inc., its gold medal for exemplary efforts in recruiting, employing, and retaining our nation's veterans.

Key Points: 
  • ALEXANDRIA, Va., Nov. 12, 2021 /PRNewswire/ -- The U.S. Department of Labor has awarded Systems Planning and Analysis, Inc., its gold medal for exemplary efforts in recruiting, employing, and retaining our nation's veterans.
  • The Honoring Investments in Recruiting and Employing American Military Veterans (HIRE Vets) Medallion Program is the only federal award recognizing exceptional achievement in veteran employment.
  • Systems Planning and Analysis, Inc. is a premier provider of innovative and data-driven knowledge-based solutions in support of complex National Security programs and defense priorities.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/systems-planning-and-analysis-i...
    SOURCE Systems Planning and Analysis, Inc.

NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference

Retrieved on: 
Friday, November 12, 2021
MPH, Lilly, Novartis, Health, J&J, NASDAQ, United States Army, Food, COVID, US Foods, Goal, COVID-19, ASPE, Letter, National, JD, Biomedical Advanced Research and Development Authority, Government, Board, Conference, Biotechnology, Company, GLOBE, Development, General officer, National Security Advisor (United States), Human services, Biology, Breakthrough therapy, Fast Track, Israel Institute for Biological Research, Patient, FDA, Dark Enlightenment, Pharmaceutical industry

RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP ), a clinical-stage, biopharmaceutical company, todayannounced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Companys business at the H.C. Wainwright 7th Annual Israel Virtual Conference.

Key Points: 
  • RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP ), a clinical-stage, biopharmaceutical company, todayannounced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Companys business at the H.C. Wainwright 7th Annual Israel Virtual Conference.
  • Details of the presentation can be found below:
    NRx Pharmaceuticals (www.nrxpharma.com) (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA.
  • The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

First Flutter-Powered Mobile Banking App in Europe

Retrieved on: 
Friday, November 12, 2021
BBB, Maintenance, Magnit, SPEAR, Fitch Ratings, Industry, Android, IOS, Moody's Investors Service, Leadership, Surf, Heart, Gold, SDK, Sibs, Banking in Russia, Technology, Forbes, Growth, Emerging market, Rosbank, National, Zenit, Central Bank of Russia, Global Custodian, ACRA, KFC, Bank, MVP, Google, Société Générale, App Store (iOS/iPadOS), SAP, Time, ATM, Cryptocurrency, Mobile phone, Video game

NEW YORK, Nov. 12, 2021 /PRNewswire-PRWeb/ -- Rosbank Business is a banking app created by Rosbank for their corporate clients.

Key Points: 
  • NEW YORK, Nov. 12, 2021 /PRNewswire-PRWeb/ -- Rosbank Business is a banking app created by Rosbank for their corporate clients.
  • We did a really great job as a single product team," Andrey Davydov, Head of Mobile, Rosbank Corporate Digital.
  • In 2021, the Rosbank Business app was awarded Gold as Best App for Financial/Insurance Company by Tagline Awards which is the largest digital-competition in Europe for the most innovative and high-quality projects.
  • Rosbank L'Hermitage Private Banking won the SPEAR's Russia Wealth Management Awards 2020 in the category "Best Foreign Bank in the Russian Federation".

International Myeloma Foundation Names Yelak Biru as CEO

Retrieved on: 
Friday, November 12, 2021
Quality of life, University, Cancer, National Comprehensive Cancer Network, Director, Caregiver, India Infoline, Education, International Myeloma Foundation, Lymphatic system, Disease, National, NCI, Multiple myeloma, Research, Board, National Cancer Institute, IMF, Data, Journal, Mayo Clinic, Walmart, B cell, PepsiCo, Patient, NIH, Pharmaceutical industry, Medicine

LOS ANGELES, Nov. 12, 2021 /PRNewswire/ -- The International Myeloma Foundation (IMF) announced today that Yelak Biru, 51, a longtime myeloma patient advocate and former Data and Analytics Executive at PepsiCo and Walmart, has been named Chief Executive Officer of the nonprofit research and patient advocacy organization.

Key Points: 
  • LOS ANGELES, Nov. 12, 2021 /PRNewswire/ -- The International Myeloma Foundation (IMF) announced today that Yelak Biru, 51, a longtime myeloma patient advocate and former Data and Analytics Executive at PepsiCo and Walmart, has been named Chief Executive Officer of the nonprofit research and patient advocacy organization.
  • Biru was diagnosed with multiple myeloma at the age of 25 while a student at the University of North Texas.
  • His fellow board member, Dr. S. Vincent Rajkumar, a myeloma specialist at Mayo Clinic, looks forward to Biru joining the foundation.
  • The International Myeloma Foundation (IMF) is the first and largest international foundation focusing specifically on multiple myeloma.

2021 "Best-of-the-Best" Corporations for Inclusion Named by NGLCC and Partners in the National Business Inclusion Consortium (NBIC)

Retrieved on: 
Friday, November 12, 2021
Color, Public policy, American, USHCC, NGLCC, Commerce, National, National LGBT Chamber of Commerce, WIPP, Bank, USBC, Bank of America, LGBT, NBIC, Workplace, Property management

"The Best-of-the-Best designation honors corporations for their commitment to America's diverse employees and business owners, which includes LGBT people, people of color, women, and people with disabilities," said NGLCC Co-Founder and President Justin Nelson. "This designation is highly competitive and is bestowed only to corporations that we see constantly striving to strengthen and celebrate diversity. These corporations being honored are true leaders in ongoing global commitments to create a better future for all diverse communities in business-- especially as we work to help all our communities recover equitably from the pandemic."

Key Points: 
  • WASHINGTON, Nov. 12, 2021 /PRNewswire/ -- The National LGBT Chamber of Commerce (NGLCC), the business voice of the LGBT community, in collaboration with its partners in the National Business Inclusion Consortium (NBIC), has named the sixth annual cohort of Best-of-the-Best list of corporations in America committed to diversity and inclusion across all communities.
  • The presentation of those honored with the Best-of-the-Best designation will be made at the Best-of-the-Best Awards held in Hollywood, Florida on November 18, as part of NGLCC's Back to Business (B2B) Summit .
  • Bank of America, a Best-of-the-Best corporation, returned for the fourth consecutive year as the evening's presenting sponsor.
  • "This designation is highly competitive and is bestowed only to corporations that we see constantly striving to strengthen and celebrate diversity.

Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes

Retrieved on: 
Friday, November 12, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Population, University, View, Boehringer Ingelheim, Degenerative disease, National academy, Therapy, IgG4-related ophthalmic disease, III, Center, Reverse transcriptase, CEO, RNA, Bill & Melinda Gates Medical Research Institute, Inflammasome, Ashton, Research, Therapeutic Targets Database, AMD, PNAS, NRTI, Severe cognitive impairment, Macular degeneration, Nature Communications, Effectiveness, Science Advances, GA, National, Toxicity, Review, AIDS, Geographic atrophy, MS, Bill, Pharmaceutical industry, Medical device

Paul Ashton, president and CEO of Inflammasome Therapeutics ( https://inflam.com ), a private company developing therapies for prevalent, degenerative diseases, will be one of the featured speakers at the Inflammasome Therapeutics Summit.

Key Points: 
  • Paul Ashton, president and CEO of Inflammasome Therapeutics ( https://inflam.com ), a private company developing therapies for prevalent, degenerative diseases, will be one of the featured speakers at the Inflammasome Therapeutics Summit.
  • This digital event, November 16-18, marks its third year as the only industry-dedicated forum that focuses specifically on inflammasome regulation and novel inflammasome therapeutics.
  • Dr. Ashton will present Insights and Learnings from Clinical Investigations of Inflammasome Activation in the Ophthalmic Setting, at 12:30 p.m.
  • Inflammasome Therapeutics is commercially developing Kamuvudines, and the company has said that it plans to bring one or more of its Kamuvudines into the clinic next year.

Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, November 12, 2021
Securities Exchange Act of 1934, Society, Safety, Fred Hutchinson Cancer Research Center, Leiden University Medical Center, American Association, Private Securities Litigation Reform Act, Fortress Biotech, Lists of diseases, Clinical trial, U.S. Securities and Exchange Commission, Pakistan Society of Neuro-Oncology, CR, NASDAQ, Follicular lymphoma, Ownership, National, Technology, American Society of Hematology, NCI, European Medicines Agency, Research, CAR, Securities Act of 1933, Forward-looking statement, Regulation, Association, Heritage, Conference, Mustang, National Cancer Institute, Annual general meeting, Translation, Hematological Cancer Research Investment and Education Act, Glioblastoma, GLOBE, City, SEC, Mayo Clinic, ORR, American Society of Clinical Oncology, NHL, Patient, Chronic lymphocytic leukemia, Patent, CLL, RAG1, Pharmaceutical industry, Lithium

WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

Key Points: 
  • WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.
  • In November 2021, Mustang announced that the company was awarded a grant of approximately $2 million from NCI of the National Institutes of Health.
  • Research and development expenses including license acquisitions were $14.7 million for the third quarter of 2021, compared to $8.3 million for the third quarter of 2020.
  • General and administrative expenses were $2.4 million for the third quarter of 2021, compared to $2.2 million for the third quarter of 2020.

UNICEF Canada calls on Canadians to Go Blue for National Child Day to recognize children’s sacrifices during the pandemic

Retrieved on: 
Friday, November 12, 2021
Convention on the Rights of the Child, Climate change, United Nations Convention to Combat Desertification, International Institute for Sustainable Development, Student, UNICEF, First Nations in Ontario, United Nations Convention, National Child Labor Committee, YMCA, Calgary Tower, UNICEF Canada, Organization, Friends, Education, CEO, Disability, UN, COVID-19, Instagram, National, When the Stars Go Blue, Facebook, BC Place, Partnership, Twitter, Mental health, GLOBE, Development, FC Volna Pinsk, CN Tower, Rights, United Nations, Adult, Vaccine, Cryptocurrency

After all theyve been through withCOVID-19, kids deserve to be celebrated, said David Morley, President and CEO, UNICEF Canada.

Key Points: 
  • After all theyve been through withCOVID-19, kids deserve to be celebrated, said David Morley, President and CEO, UNICEF Canada.
  • National ChildDay and World Childrens Day is a moment to reflect and thank them for all they have done both here in Canada and around the world.
  • To show their support, Canadians can wear blue, and colour theirneighbourhoods, organizations,and the internet blue to recognize childrens sacrifices andsay thank you.
  • On November 19, the day before National Child Day/World Childrens Day, UNICEF Canada will be hosting a virtual Youth Activism Summit , bringing together young people, partners, adult influencers and decision-makers.

BlackSky Technology Inc. Reports Third Quarter 2021 Results

Retrieved on: 
Friday, November 12, 2021
Other Transport, Networks, Satellite, Transport, Technology, Securities Exchange Act of 1934, National Geospatial-Intelligence Agency, Spaceflight, Inc., Software as a service, Spectra, Traction, Industry, Contract, Palantir Technologies, Government, Engineering, National Aeronautic Association, Security (finance), NRO, Technology, Veteran, NASA, Machine learning, Depreciation, COVID-19, Artificial intelligence, Research, National, Securities Act of 1933, Software, Forward-looking statement, PLTR, EBITDA, Partnership, U.S. Securities and Exchange Commission, Company, NGA, Solution, GAAP, SEC, NYSE, National Reconnaissance Office, General counsel, Weapon, Communications satellite, Animal, Reinsurance, Risk management

BlackSky Technology Inc. (BlackSky or the Company) (NYSE: BKSY), a leading technology platform providing real-time geospatial intelligence and global monitoring, today announced its results for the third quarter of 2021.

Key Points: 
  • BlackSky Technology Inc. (BlackSky or the Company) (NYSE: BKSY), a leading technology platform providing real-time geospatial intelligence and global monitoring, today announced its results for the third quarter of 2021.
  • Imagery deliveries under the contract increased 100% from the second quarter to the third quarter as BlackSky further integrates its solutions into the day-to-day operations of the government.
  • Third Quarter 2021 Financial Highlights:
    Total revenue for the third quarter of 2021 was $7.9 million, up 49% from the prior year period.
  • BlackSky ended the third quarter of 2021 with $198 million of cash on its balance sheet.